-
公开(公告)号:NZ593068A
公开(公告)日:2012-12-21
申请号:NZ59306804
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , BOSS JEFFREY W
IPC: C07H21/04 , A61K39/395 , A61P19/02 , A61P37/06 , C07K16/00 , C07K16/24 , C12N15/00 , G01N33/53 , G01N33/68
Abstract: Disclosed is an isolated monoclonal antibody, or antigen binding portion thereof, capable of binding human IL-18, wherein the antibody, or antigen binding portion thereof, comprises: a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the heavy chain variable region CDR3 sequence comprises an amino acid sequence of residues 99-110 of SEQ ID NO:6, or an amino acid sequence of residues 99-110 of S EQ ID NO:6 containing conservative amino acid substitutions. Further disclosed is an isolated monoclonal antibody, or antigen binding portion thereof, capable of binding human IL-18, that comprises a light chain variable region (VL) comprising SEQ ID NO:7.
-
公开(公告)号:SI1685152T1
公开(公告)日:2012-06-29
申请号:SI200431865
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
-
公开(公告)号:NZ582097A
公开(公告)日:2011-07-29
申请号:NZ58209704
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
IPC: C07K16/00 , A61K39/395 , A61P19/02 , A61P37/06 , C07H21/04 , C07K16/24 , C12N15/00 , G01N33/53 , G01N33/68
Abstract: Provided is an isolated monoclonal antibody, or antigen binding portion thereof, capable of binding human IL-18, wherein the antibody, or antigen binding portion thereof, comprises: a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the heavy chain variable region CDR3 sequence comprises a specified amino acid sequence. The antibody can be used to treat various immunological and infectious diseases.
-
公开(公告)号:CR11179A
公开(公告)日:2010-05-27
申请号:CR11179
申请日:2009-12-18
Applicant: ABBOTT LAB
Inventor: EBERT ULRICO , HILLEN HEINZ , KELLER PATRICK , STRIEBINGER ANDREAS R , LABKOVSKY BORIS , HINTON PAUL R , JUAN VERONICA M , STEFAN BARGHORN
Abstract: Proteinas de union, y en particular, anticuerpos humanizados que pueden usarse, por ejemplo, en el diagnostico, el tratamiento y la prevencion de la enfermedad de Alzheimer y condiciones relacionadas.
-
公开(公告)号:MX2009012950A
公开(公告)日:2010-03-26
申请号:MX2009012950
申请日:2008-05-30
Applicant: ABBOTT LAB
Inventor: HINTON PAUL R , LABKOVSKY BORIS , HILLEN HEINZ , KELLER PATRICK , BARGHORN STEFAN , EBERT ULRICH , STRIEBINGER ANDREAS R , JUAN VERONICA M
Abstract: La presente invención se refiere a proteínas de unión, y en particular, a anticuerpos humanizados que pueden usarse, por ejemplo, en el diagnóstico, el tratamiento y la prevención de la enfermedad de Alzheimer y condiciones relacionadas.
-
公开(公告)号:DOP2009000269A
公开(公告)日:2009-12-15
申请号:DO2009000269
申请日:2009-11-27
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor: HINTON PAUL R , BARGHORN STEFAN , EBERT ULRICH , HILLEN HEINZ , KELLER PATRICK , STRIEBINGER ANDREAS R , LABKOVSKY BORIS , JUAN VERONICA M
Abstract: Proteínas de unión, y en particular, anticuerpos humanizados que pueden usarse, por ejemplo, en el diagnóstico, el tratamiento y la prevención de la enfermedad de Alzheimer y condiciones relacionadas.
-
公开(公告)号:AR066794A1
公开(公告)日:2009-09-09
申请号:ARP080102298
申请日:2008-05-30
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor: LABKOVSKY BORIS , HINTON PAUL R , HILLEN HEINZ , JUAN VERONICA R , TERRY STEPHEN E , EBERT ULRICH , KELLER PATRICK , BARHORN STEFAN
IPC: C07K7/00 , C07K14/435 , C07K16/18 , C12N15/13 , C12N15/63 , C12P21/00 , A61K39/395
Abstract: Anticuerpos para uso en diagnostico, tratamiento y prevencion de la enfermedad de Alzheimer y enfermedades relacionadas. Se revela una proteína de union que comprende un dominio de union a antígeno que se une al globulomero beta amiloide (20-42), donde dicho dominio de union a antígeno comprende al menos una CDR que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: CDR-VH1. X1-X2-X3-X4-X5-X6-X7 (SEQ ID Ns 5), donde: X1 es T o S; X2 es F o Y; X3 es Y o A; X4 es I o M; y X5 es H o S; CDR-VH2. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 X16-X17 (SEQ ID Ns 6), donde: X1 es M o S; X2 es I; X3 es G o H; X4 es P o N; X5 es G o R; X6 es S o G; X7 es G o T; X8 es N o l; X9 es T o F; X10 es Y; X11 es Y o L; X12 es N o D; X13 es E o S; X14 es M o V; x15 es F o K; X16 es K o G; y X17 es O o no está presente; CDR-VH3. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (SEQ ID Ns 7), donde: X1 es A o G; X2 es K o R; X3 es S; X4 es A o N; X5 es R o S; X6 es A o Y; X7 es A; X8 es W o M; X9 es F o D; X10 es A o Y; y X11 es Y o no está presente; CDR-VL1. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 X16 (SEQ ID Ns 8), donde: X1 es R; X2 es S; X3 es S o T; X4 es Q; X5 es S o T; X6 es V o L; X7 es V; X8 es Q o H; X9 es S o R; X10 es N; X11 es G; X12 es N o D; X13 es T; X14 es Y; X15 es N o L y X16 es E; CDR-VL2. X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID Ns 9), donde: X1 es K; X2 es V; X3 es S; X4 es N; X5 es R; X6 es F; y X7 es S; y CDR-VL3. X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID Ns 10), donde: X1 es F; X2 es Q; X3 es G; X4 es S; X5 es H; X6 es V; X7 es P; X8 es P o Y; y X9 es T. También se describe un anticuerpo construido que comprende dicha proteína de union; un anticuerpo conjugado que comprende el anticuerpo construido; una molécula de ácido nucleico aislada que codifica una proteína de union; un vector que comprende dicha molécula de ácido nucleico aislada; célula huésped aislada que comprende dicho vector; método para producir una proteína capaz de unirse al globulomero Abeta(20-42) y proteína que se obtiene; composicion para la liberacion de una proteína de union; el uso de una composicion en la fabricacion de un medicamento; composicion farmacéutica; el uso de la proteína de union en la fabricacion de un medicamento reducir la actividad del globulomero Abeta(20-42); el uso de la proteína de union en la fabricacion de un medicamento para reducir la actividad del globulomero Abeta(20-42) humano; método para diagnosticar la enfermedad de Alzheimer; vacuna y método para detectar una secuencia de un péptido beta amiloide mutante en un paciente sospechado de padecer la enfermedad de Alzheimer.
-
公开(公告)号:HK1098762A1
公开(公告)日:2007-07-27
申请号:HK07101057
申请日:2007-01-30
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
IPC: A61K20060101 , A61P20060101 , C07K20060101 , C07K16/24 , G01N20060101 , G01N33/68
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号:NZ520392A
公开(公告)日:2005-04-29
申请号:NZ52039201
申请日:2001-02-09
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , DIXON RICHARD W , ROGUSKA MIKE , WHITE MICHAEL , LABKOVSKY BORIS , SALFELD JOCHEN , DUNCAN ALEXANDER ROBERT , BROCKLEHURST SIMON MARK , MANKOVICH JOHN , SHORROCK CELIA PATRICIA , THOMPSON JULIA ELIZABETH , LENNARD SIMON NICHOLAS
IPC: A61K39/395 , A61K45/00 , A61P1/04 , C12N15/02 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/02 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
Abstract: An isolated human monoclonal antibody capable of binding to human IL-18 is described. The antibody can be used in the manufacture of a medicament for inhibiting human IL-18 activity, and for detecting human IL-18 activity in a sample.
-
公开(公告)号:PL188192B1
公开(公告)日:2004-12-31
申请号:PL32841197
申请日:1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor: SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
-
-
-
-
-
-
-
-